Overview
Xevant provides data analytics solutions for the pharmacy benefit management (PBM) sector, helping PBMs, health plans, TPAs, and brokers manage pharmacy spend more efficiently. Its analytics platform automates data analyses to deliver real-time insights and alerts, while offering services like implementation, customization, training, and ongoing support. This turnkey package combines software with hands-on assistance and is tailored specifically to PBM data to identify hidden cost drivers. The goal is to reduce overall pharmacy spend, improve patient outcomes, and increase client satisfaction and retention through data-driven optimization.
Work here?Claim your company
Simplify's take
What believers are saying
- October 2025 VerX expansion added Cortex, Pulse, Axis, and Nudge capabilities.
- Xevant's 2024 report shows 13% plan-paid cost growth, supporting demand for savings tools.
- 2025 biosimilar adoption gains and GLP-1 waste create immediate buyer urgency.
What critics are saying
- August 2026 secured-party sale targets Xevant's IP, customer list, and xevant.com.
- Black Feather says Xevant owes $26.8 million, signaling severe distress before September 2026.
- A buyer can strip the brand and platform, leaving the company existentially broken.
What makes Xevant unique
- VerX unifies claim-level analytics, routing, and member nudges in one RxTech workflow.
- Xevant’s 2025 Biosimilar Dashboard targets biologic spend with real-time prescriber intelligence.
- Its 2024 Drug Trend Report gives clients category benchmarks across GLP-1s and specialty drugs.
Help us improve and share your feedback! Did you find this helpful?